Abstract: The present invention provides a minimally invasive surgical applicator device. The device is useful in the application of bone wax during surgical procedures to halt or reduce bone bleeding. The device may be sterilized for re-use or may be made disposable.

Abstract: The present invention provides a minimally invasive surgical applicator device. The device is useful in the application of bone wax during surgical procedures to halt or reduce bone bleeding. The device may be sterilized for re-use or may be made disposable.

Abstract: The present invention provides a minimally invasive surgical applicator device. The device is useful in the application of bone wax during surgical procedures to halt or reduce bone bleeding. The device may be sterilized for re-use or may be made disposable.

Abstract: A nail file, including a file sheet and a handle, wherein at least the file sheet is made of biscuit porcelain, the file sheet containing an abrasive agent.

Abstract: A process for production of hydrogen and/or carbon monoxide rich gas from gaseous or liquid hydrocarbon feed-stock comprising the following steps: (a) desulphurisation of the hydrocarbon feed (1), mixing the feed (1) with steam (4) produced from waste heat in the process, feeding the mixture (6, 7) to a steam reforming section (8, 9) for conversion of the hydrocarbon feed by reaction with steam to form a process gas (12) comprising a mixture of hydrogen, carbon monoxide, carbon dioxide, residual methane and excess steam, (b) cooling the process gas (12) by steam production, (c) separating hydrogen and/or carbon monoxide (21) by conducting the process gas through a hydrogen and/or carbon monoxide purification section (20), (d) adding essentially all off-gas (22) from the purification section (20) as fuel to the reforming section (8, 9) to provide heat for the reforming reaction, (e) recovering hot flue gas (32) from the reforming section and cooling the hot flue gas at least partly by steam production, (f) rec

Abstract: A conjugate exhibiting interferon gamma activity and comprising at least one first non-polypeptide moiety covalently linked to an IFG polypeptide, the polypeptide comprising an amino acid sequence that differs from that of a parent IFNG polypeptide in at least one introduced and/or at least one removed amino acid residue comprising an attachment group for the non-polypeptide moiety. The conjugate may be used for treatment of various diseases.

Abstract: Glycosylated polypeptides comprising the primary structure NH2-X-Pp-COOH, wherein X is a peptide addition comprising or contributing to a glycosylation site, and Pp is a polypeptide of interest or comprising the primary structure NH2-Px-X-Py-COOH, wherein Px is an N-terminal part of a polypeptide Pp of interest, Py is a C-terminal part of said polypeptide Pp, and X is a peptide addition comprising or contributing to a glycosylation site are provided. The glycosylated polypeptides possess improved properties as compared to the polypeptide of interest.

Abstract: A manicure file where a part of it is made from thermo hardened armoured glass with an abrasive surface from 1-10 um (micrometer) where the glass is build into a hard plastic handle and have extra a plastic case as a protection

Abstract: The present invention relates to novel full-length interferon gamma (IFNG) polypeptide variants having interferon gamma activity. The full-length interferon gamma polypeptide variants of the invention are obtained by performing selected modifications in the C-terminal part of the molecule. The full-length interferon gamma polypeptide variants of the invention are useful in therapy, in particular for the treatment of interstitial pulmonary diseases, such as idiopathic pulmonary fibrosis.

Abstract: The present invention relates to novel interferon gamma polypeptide variants having interferon gamma (IFNG) activity, methods for their preparation, pharmaceutical compositions comprising the polypeptide variants and their use in the treatment of diseases, in particular for the treatment of interstitial pulmonary diseases, such as idiopathic pulmonary fibrosis. These novel polypeptide variants all comprise the substitution S99T as compared to the amino acid sequence of huIFNG or fragments thereof. By performing this mutation the naturally occurring N-glycosylation site present at position 97 is significantly better utilized. Preferably, the variants comprise further modifications, e.g. in order to increase the AUC of such variants when administered subcutaneously.

Abstract: When interferon gamma (IFNG) is produced in mammalian cell lines a heterogenous population of IFNG polypeptides is obtained due to C-terminal processing of the IFNG polypeptide. Clearly, this constitutes a severe problem in that valuable polypeptide material is lost and, further, it is necessary to carry out time-consuming and cumbersome purification in order to obtain a homogenous population of active IFNG polypeptides having the desired length. It has now been found that an IFNG fragment containing 132 amino acid residues (truncated at the nucleotide level by introducing a stop-codon after the codon encoding amino acid residue no. 132) does not undergo C-terminal truncation or, at least, is not significantly C-terminally truncated. Furthermore, as the IFNG fragment containing 132 amino acid residues is active, this opens up the possibility of producing a homogenous active IFNG polypeptide in eukaryotic host cells, such as CHO cells.